Sugi Predict

Sugi Predict / Compounds / SCHEMBL2392486

SCHEMBL2392486

SCHEMBL2392486

CC(C)(C)OC(=O)NC1(C(N)=O)CC1

nearest known ligand 0.38

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KMT2A Q03164 2/20 0.38
▸ MEN1 O00255 1/20 0.38
▸ MAPK1 P28482 1/20 0.38
▸ KDM4E B2RXH2 1/20 0.36
▸ MAOA P21397 1/20 0.36
▸ MAOB P27338 1/20 0.36
▸ GAA P10253 3/20 0.36
▸ GHSR Q92847 1/20 0.35
▸ CTSL P07711 1/20 0.35
▸ APLNR P35414 1/20 0.34
▸ NFKB1 P19838 1/20 0.33
▸ NFKB2 Q00653 1/20 0.33
▸ RELA Q04206 1/20 0.33
▸ TDP1 Q9NUW8 1/20 0.33
▸ CA12 O43570 1/20 0.33
▸ CA14 Q9ULX7 1/20 0.33
▸ BTK Q06187 1/20 0.33
▸ CA1 P00915 1/20 0.33
▸ CA2 P00918 1/20 0.33
▸ CA7 P43166 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4742076 0.93 KMT2A (0.36) KMT2AMEN1MAPK1KDM4EMAOA
SCHEMBL2716648 0.93 KMT2A (0.36) KMT2AMEN1MAPK1KDM4EMAOA
SCHEMBL20054418 0.92 TSHR (0.37) KMT2AMEN1MAPK1KDM4EMAOA
SCHEMBL2087505 0.91 GAA (0.36) KMT2AMEN1MAPK1KDM4EMAOA
SCHEMBL2086150 0.90 KMT2A (0.38) KMT2AMEN1MAPK1KDM4EMAOA
SCHEMBL3955815 0.88 KMT2A (0.54) KMT2AMEN1MAPK1KDM4EMAOA
SCHEMBL5128975 0.88 USP2 (0.37) KMT2AMEN1MAPK1GAAGHSR
SCHEMBL142425 0.87 MEN1 (0.37) KMT2AMEN1MAPK1MAOAMAOB
SCHEMBL2084664 0.87 GHSR (0.36) KMT2AMEN1MAPK1KDM4EMAOA
Hydrochloric Acid SCHEMBL2392949 0.85 SPHK1 (0.37) KMT2AMEN1MAPK1MAOAMAOB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 47 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20250304564-A1 NOVEL KV3 MODULATORS AUTIFONY THERAPEUTICS LTD (GB) 2025-10-02 — — US disclosed
US-12358901-B2 KV3 modulators AUTIFONY THERAPEUTICS LIMITED (GB) 2025-07-15 — — US disclosed
WO-2025104079-A1 SALICYLIC ACID AND PICOLINIC ACID DERIVATIVES AS INHIBITORS OF ENERGY COUPLING FACTOR (ECF) TRANSPORTERS FOR THE TREATMENT OF BACTERIAL INFECTIONS Helmholtz-Zentrum für Infektionsforschung GmbH (DE) 2025-05-22 — — WO disclosed
CN-115066424-B Kv3 modulators 奥蒂福尼疗法有限公司 2024-12-27 — — CN disclosed
EP-3867247-B1 NOVEL COMPOUNDS AUTIFONY THERAPEUTICS LTD (GB) 2024-07-24 — — EP disclosed
EP-4364804-A2 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION Janssen Pharmaceutica NV (BE) 2024-05-08 — — EP disclosed
US-11897900-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction JANSSEN PHARMACEUTICA NV (BE) 2024-02-13 — — US disclosed
EP-3833662-B1 INHIBITORS OF KEAP1-NRF2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2024-01-17 — — EP disclosed
EP-4100402-A1 KV3 MODULATORS Autifony Therapeutics Limited (GB) 2022-12-14 — — EP disclosed
US-20220315604-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION JANSSEN PHARMACEUTICA NV (BE) 2022-10-06 — — US disclosed
EP-2225238-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZOÝ1,2- ¨IMIDAZOLE-3- CARBOXYLIC ACID AMIDES Boehringer Ingelheim International GmbH (DE) 2010-09-08 — — EP disclosed
US-20100144730-A1 PYRIDINONYL PDK1 INHIBITORS SUNESIS PHAMACEUTICALS (US) 2010-06-10 — — US disclosed
WO-2009070485-A1 DERIVATIVES OF 6,7-DIHYDRO-5H-IMIDAZO[1,2-α]IMIDAZOLE-3- CARBOXYLIC ACID AMIDES BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) 2009-06-04 — — WO disclosed
EP-2038272-A2 PYRIDINONYL PDK1 INHIBITORS Sunesis Pharmaceuticals, Inc. (US) 2009-03-25 — — EP disclosed
WO-2008005457-A2 PYRIDINONYL PDK1 INHIBITORS SUNESIS PHARMACEUTICALS (US) 2008-01-10 — — WO disclosed
US-7045545-B1 Aminoalkylbenzofurans as serotonin (5-HT(2c)) agonists ELI LILLY AND COMPANY (US) 2006-05-16 — — US disclosed
US-6936606-B2 Cyanoamido-containing heterocyclic compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2005-08-30 — — US disclosed
EP-1434769-A2 COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS INC. (US) 2004-07-07 — — EP disclosed
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases BOEHRINGER INGELHEIM PHARMACEUTICALS INC. 2004-04-01 — — US disclosed
WO-2003029200-A2 COMPOUNDS USEFUL AS REVERSIBLE INHIBITORS OF CYSTEINE PROTEASES BOEHRINGER INGELHEIM PHARMACEUTICALS, INC. (US) 2003-04-10 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220315604-A1 INHIBITORS OF KEAP1-Nrf2 PROTEIN-PROTEIN INTERACTION KEAP1, NFE2L2, HMOX1 KMT2A 1295/4885MEN1 4859/4885MAPK1 1279/4885
US-12358901-B2 KV3 modulators KCNN3, KCNA3, KCNH3 KMT2A 614/4885MEN1 1261/4885MAPK1 716/4885
US-20040063679-A1 Compounds useful as reversible inhibitors of cysteine proteases CTSS, CTSK, CTSB KMT2A 4544/4885MEN1 3211/4885MAPK1 2874/4885
US-11897900-B2 Inhibitors of KEAP1-Nrf2 protein-protein interaction KEAP1, NFE2L2, HMOX1 KMT2A 1295/4885MEN1 4859/4885MAPK1 1279/4885
US-20100144730-A1 PYRIDINONYL PDK1 INHIBITORS PDK1, PDK2, PDK3 KMT2A 1202/4885MEN1 1555/4885MAPK1 530/4885
US-20250304564-A1 NOVEL KV3 MODULATORS KCNN3, KCNA3, KCND3 KMT2A 651/4885MEN1 1478/4885MAPK1 714/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.